Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Appointed CFO
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Forest Laboratories, LLC (FRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/03/2014 8-K Form 8-K - Current report
07/02/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee"
07/02/2014 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Certificate of Formation of Tango Merger Sub 2 LLC",
"Limited Liability Company Agreement of Forest Laboratories, LLC",
"Second Amendment to Employment Agreement, between Forest and Brenton L. Saunders",
"Second Amendment to Employment Agreement, between Forest and Karen Ling",
"Actavis Completes Forest Laboratories Acquisition"
06/18/2014 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest"
06/13/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Waiver and Amendment, to the Registration Rights Agreements and January 31, 2014, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes Release Date:"
06/09/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes Release Date:"
05/28/2014 8-K Other Events
05/22/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes Release Date:"
05/20/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/29/2014 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR FOURTH QUARTER 2014"
04/28/2014 8-K/A Other Events, Financial Statements and Exhibits
Docs: "Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including that the transactions may not be timely completed, if at all, that prior to completion of the transactions, Furiex's business may experience significant disruptions due to transaction-related uncertainty or other factors, the timing and the benefits of the business combination transaction, the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule, the requirement that Furiex's security holders approve the transaction, the risk that the businesses will not be integrated successfully, the difficulty of predicting FDA approvals, the accept..."
04/28/2014 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Revenue Rights Purchase Agreement, by and between Forest Laboratories, Inc. and RPI Finance Trust",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty",
"E-mail, from Brenton L. Saunders, the Chief Executive Officer of Forest Laboratories, Inc., to employees of Forest Laboratories, Inc",
"Investor Presentation",
"Transcript"
04/28/2014 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Revenue Rights Purchase Agreement, by and between Forest Laboratories, Inc. and RPI Finance Trust",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty",
"E-mail, from Brenton L. Saunders, the Chief Executive Officer of Forest Laboratories, Inc., to employees of Forest Laboratories, Inc",
"Investor Presentation"
02/19/2014 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Agreement and Plan of Merger, by and among Actavis plc, Tango US Holdings Inc., Tango Merger Sub 1 LLC, Tango Merger Sub 2 LLC and Forest Laboratories, Inc. (schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K)",
"Amendment to Employment Agreement, by and between Forest Laboratories, Inc. and Brenton L. Saunders"
02/18/2014 8-K Investor presentation
Docs: "Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction",
"Investor Presentation"
02/03/2014 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Indenture for the 4.375% Senior Notes, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Indenture for the 4.875% Senior Notes, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Registration Rights Agreement, by and among Forest Laboratories, Inc., as issuer, and Morgan Stanley & Co. LLC, as representative of the initial purchasers",
"Forest Laboratories, Inc. Completes $2.9B Acquisition of Aptalis"
01/27/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Forest Laboratories, Inc. Prices Offering of $1.8 Billion in Senior Notes Release Date:"
01/27/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Consent of PricewaterhouseCoopers LLP",
"Disclosures regarding Forest Laboratories, Inc",
"Forest Laboratories, Inc. Announces Private Placement of Senior Notes Release Date:",
"Audited consolidated balance sheets of Aptalis Holdings, Inc., as of September 30, 2013 and 2012, and the related consolidated statements of income, comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended September 30, 2013, including the notes thereto, and Schedule II",
"Unaudited pro forma combined statements of operations for the six months ended September 30, 2013 and for the year ended March 31, 2012, unaudited pro forma combined balance sheet as of September 30, 2013, and the accompanying notes"
01/21/2014 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR THIRD QUARTER 2014"
01/15/2014 8-K Entry into a Material Definitive Agreement
01/08/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among FRX Churchill Holdings, Inc., FRX Churchill Sub, Inc., Forest Laboratories, Inc. and Aptalis Holdings, Inc",
"Commitment Letter, among Forest Laboratories, Inc. and Morgan Stanley Senior Funding, Inc",
"Forest Laboratories to Acquire Aptalis for $2.9 Billion in Cash Acquisition is Immediately Accretive - Adds Nearly $700 million to FY2015 Revenues - Company Expects to Achieve $125 Million in Synergies by FY2016 - Accretive to FY2015 Non-GAAP EPS by Approximately $0.78 Diversifies Forest Offerings in Key Therapeutic Areas & Geographies"
12/11/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, by and among Forest Laboratories, Inc. and Wells Fargo Bank, National Association, as trustee",
"Registration Rights Agreement, by and among Forest Laboratories, Inc. and Morgan Stanley & Co. LLC, as representative of the initial purchasers",
"Forest Laboratories Announces Appointments to its Executive Team"
12/05/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Forest Laboratories, Inc. Upsizes and Prices Offering of $1.2 Billion of Senior Notes Due 2021 Release Date:"
12/02/2013 8-K Form 8-K - Current report
10/22/2013 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR SECOND QUARTER 2014 DILUTED EARNINGS PER SHARE OF $0.26 INCLUDING EFFECT OF $0.10 PER SHARE OF ACQUISITION AMORTIZATION"
10/04/2013 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Stock Purchase Agreement between Forest and Brenton L. Saunders",
"Employee Restricted Stock Agreement (Time-Based) granted to Brenton L. Saunders on October 1, 2013",
"Change of Control Employment Agreement between Forest and Brenton L. Saunders"
06/11/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nomination and Standstill Agreement by and between Forest Laboratories, Inc., Carl C. Icahn, Vincent J. Intrieri, High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital LP, Icahn Onshore LP, Icahn Offshore LP, and Beckton Corp",
"FOREST LABORATORIES APPOINTS NEW INDEPENDENT DIRECTOR Vincent J. Intrieri Joins Expanded, 11-Member Board"
04/23/2013 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR FOURTH QUARTER 2013 EARNINGS PER SHARE OF $0.17 INCLUDING $0.08 PER SHARE OF ACQUISITION AMORTIZATION"
01/15/2013 8-K Quarterly results
Docs: "REPORTS FISCAL YEAR 2013 THIRD QUARTER EARNINGS"
10/23/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 1 to the Credit Agreement dated December 7, 2007, by and among Forest Laboratories, Inc., Forest Laboratories Holdings Limited, Forest Laboratories Ireland Limited, Forest Finance B.V., Forest Laboratories UK Limited, the lenders party thereto, and JPMorgan Chase Bank, N.A"
10/19/2012 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR SECOND QUARTER 2013 GAAP EARNINGS PER SHARE OF $0.08"
08/28/2012 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designations for Forest Laboratories, Inc. Series B Junior Participating Preferred Stock",
"Rights Agreement, between Forest Laboratories, Inc. and Computershare Shareowner Services LLC, which includes the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C",
"FOREST LABORATORIES ADOPTS STOCKHOLDER RIGHTS PLAN AND DECLARES DIVIDEND DISTRIBUTION OF PREFERRED SHARE PURCHASE RIGHTS"
08/24/2012 8-K/A Submission of Matters to a Vote of Security Holders
07/18/2012 8-K Quarterly results
Docs: "FOREST LABORATORIES, INC. REPORTS FISCAL YEAR FIRST QUARTER 2013 EARNINGS PER SHARE OF $0.21"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy